The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) the Eli Lilly’s etesevimab in combination with another AbCellera and Eli Lilly’s monoclonal antibody bamlanivimab for treating mild to moderate COVID-19 in patients 12 years or older. Both drug therapies should be administered through a single intravenous infusion as soon as possible after a positive COVID-19 test. Carl Hansen, president and chief executive officer of AbCellera, stated, “With this EUA for bamlanivimab and etesevimab together, there are more treatment options for patients at high risk for hospitalization and another layer of protection against the emergence of new viral variants.”
Read more here.
More on: News Regulatory